DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Mr. Kevin  Sun M.B.A.

Chief Financial Officer, Treasurer & Secretary

Ms. Jennifer  Eilemberg

Chief Compliance Officer

Mr. Ray  Akhavan Esq., J.D.

General Counsel

Mr. Steve E. Kunszabo

Senior Director of Investor Relations

Dr. Steven  Stone Ph.D.

Senior Vice President of Research & Development

Mr. Bret  Christensen

President, Chief Executive Officer & Director

Dr. Loren  Clarke M.D.

Chief Medical Officer

Mr. William W. Zondler

Chief Information Officer

Dr. Burkhard  Jansen M.D.

Chief Medical Affairs Officer

Mr. Mark  Aguillard

Chief Commercial Officer

Nombre	Capitalización
Thyrocare Technologies Limited	0M
China Health Group Inc.	0M
Revvity, Inc.	0M
Sotera Health Company	0M
Standard BioTools Inc.	0M
IDEXX Laboratories, Inc.	0M
Myriad Genetics, Inc.	0M
Abingdon Health Plc	0M
China Biotech Services Holdings Limited	0M
Sonic Healthcare Limited	0M
Quest Diagnostics Incorporated	0M

DermTech, Inc.

DermTech, Inc. Lista de competidores

Principales competidores